Brainstorm Cell Therapeutics Inc  

(Public, NASDAQ:BCLI)   Watch this stock  
Find more results for OTC:BCLI
+0.13 (4.74%)
Oct 9 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 2.71 - 2.89
52 week 2.17 - 8.47
Open 2.82
Vol / Avg. 95,434.00/118,642.00
Mkt cap 50.64M
P/E     -
Div/yield     -
EPS -0.58
Shares 18.48M
Beta 0.29
Inst. own 12%
Nov 11, 2015
Q3 2015 Brainstorm Cell Therapuetics Inc Earnings Release (Estimated) Add to calendar
Sep 10, 2015
Brainstorm Cell Therapuetics Inc at Rodman & Renshaw Global Investment Conference
Aug 13, 2015
Q2 2015 Brainstorm Cell Therapuetics Inc Earnings Call - Webcast
Aug 13, 2015
Q2 2015 Brainstorm Cell Therapuetics Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '15) 2014
Net profit margin - -
Operating margin - -
EBITD margin - -
Return on average assets -42.50% -126.34%
Return on average equity -48.46% -196.43%
Employees 16 -
CDP Score - -


3 University Plaza Drive, Suite 320
United States - Map
+1-201-4880460 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Brainstorm Cell Therapeutics Inc. is a biotechnology company. The Company is developing adult stem cell therapies for debilitating neurodegenerative disorders, such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis and Parkinson's disease, among others. The Company's NurOwn technology is based on a differentiation protocol, which induces differentiation of the bone marrow-derived mesenchymal stem cells into neuron-supporting cells, MSC-NTF cells, capable of releasing several neurotrophic factors, including Glial-derived neurotrophic factor, Brain-derived neurotrophic factor, Vascular endothelial growth factor and Hepatocyte growth factor, which are critical for the growth, survival and differentiation of developing neurons. NurOwn is in clinical development for the treatment of ALS. It has completed two clinical trials of NurOwn in patients with ALS at Hadassah Medical Center. It has been granted Fast Track designation and Orphan Status.

Officers and directors

Irit Arbel Chairman of the Board
Age: 55
Bio & Compensation  - Reuters
Chaim Lebovits Chief Executive Officer
Age: 44
Bio & Compensation  - Reuters
Yoram Bibring Chief Financial Officer, Treasurer
Age: 57
Bio & Compensation  - Reuters
Uri Yablonka Chief Operating Officer, Director
Age: 38
Bio & Compensation  - Reuters
Alla Patlis Controller
Age: 28
Bio & Compensation  - Reuters
Mordechai Friedman Independent Director
Age: 62
Bio & Compensation  - Reuters
Alon Pinkas Independent Director
Age: 54
Bio & Compensation  - Reuters
Chen Schor CPA Independent Director
Age: 42
Bio & Compensation  - Reuters
Robert G. Shorr Ph.D. Independent Director
Age: 61
Bio & Compensation  - Reuters
Malcolm Taub Independent Director
Age: 69
Bio & Compensation  - Reuters